Dr. Morgan the Evolution of Treatment in Multiple Myeloma

Gareth J. Morgan, MD, PhD, a professor in the Department of Medicine and director of Multiple Myeloma Research at NYU Langone Health’s Perlmutter Cancer Center, discusses the evolution of treatment options in multiple myeloma.

In the last 2 decades, the armamentarium for patients with multiple myeloma has expanded from 1 standard of care to many novel modalities, says Morgan.

Historically, multiple myeloma was characterized by patients achieving remission but relapsing shortly thereafter, explains Morgan. However, the development of BCMA-targeted agents has led to higher remission rates.

The addition of other novel therapies may prolong the duration of remission in this patient population, concludes Morgan.